April 25th 2024
In LEVEL-UP, upadacitinib demonstrated superiority over dupilumab in achieving EASI-90 and little to no itch at week 16.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
New Phase 3 Data on Long-Term Efficacy of Upadacitinib in Atopic Dermatitis Presented at EADV
October 11th 2023The data presents compelling evidence for the sustained efficacy and safety of the oral JAK1 inhibitor in the treatment of moderate to severe atopic dermatitis over an extended 140-week period.
Expert Opinions on the Role of Corticosteroids in Dermatological Conditions
October 3rd 2023James Q Del Rosso, DO and TJ Chao, MPAS, PA-C discuss the role of topical agents in the management of dermatological conditions reviewing their position and role within the treatment landscape for dermatological conditions.